XLRN News and Press, Acceleron Pharma Inc. From 02/24/21

Acceleron Pharma (NASDAQ:XLRN) is scheduled to announce Q4 earnings results on Thursday, February 25th, after market close.The consensus EPS Estimate is -$0.55 (vs. $-0.44 in year ago quarter) and the consensus Revenue Estimate is $32.31M (-17.9% Y/Y).Over the last 2 years, XLRN has beat...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth quarter and full year 2020 financial results. The webcast will be accessible under "Events & Presentations" in the...

Bristol Myers Squibb Company ([[BMY]] -0.2%) Bristol Myers Squibb Canada and Acceleron Pharma ([[XLRN]] -2.6%)announce that Health Canada has approved REBLOZYL (luspatercept for injection) for the treatment of certain patients with transfusion-dependent anemia. The approval is for u...

REBLOZYL ® , an erythroid maturation agent, is the first and only of its kind approved for use in Canada Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL ® (luspatercept for injection) for ...

- Acceleron expects to report approximately $23.0 million in royalty revenue for Q4 2020 from approximately $115 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb - - Acceleron expects to report approximately $54.8 million in r...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron’s President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 11 at 10:00 a.m...

Commenting on the proposed merger between Alexion (ALXN) and AstraZeneca (AZN), Piper Sandler highlights the ‘durability’ of large biotech businesses, ‘with Astra pointing to double-digit EPS accretion in years 1-3’ from the deal.“If the market doe...

The European Commission has granted Orphan Designation to Acceleron Pharma's (XLRN) sotatercept for the treatment of pulmonary arterial hypertension ((PAH)).The company is currently advancing a Phase 3 trial for sotatercept, beginning with the registrational trial known as STELLAR e...

– Sotatercept received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in PAH in 2019 – – In the spring of 2020, sotatercept received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the...

The FDA has designated Orphan Drug status to Acceleron Pharma's (XLRN) ACE-1334 for the treatment of systemic sclerosis, an autoimmune rheumatic disease characterized by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs.The Company intend...